ArticleRSC advances2026
Free radical scavenging and antibacterial effects of pigskin peptide-functionalized NU-1000 composites.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pigskin peptides (PSPs) are bioactive collagen hydrolysates known for their antioxidant, antibacterial, and other biomedical potentials; however, their direct application is limited by poor environmental stability. Herein, we report the use of NU-1000, a robust zirconium-based metal-organic framework (MOF), as a delivery platform. A PSP-loaded NU-1000 composite, denoted as PSPs-1@NU-1000-2, was successfully constructed using PSPs with a molecular weight below 3000 Da, and this composite exhibited superior bioactivity. Structural and morphological characterization by FTIR, SEM, XRD, and BET confirmed the successful incorporation of PSPs into NU-1000. Notably, compared with free PSPs, the PSPs-1@NU-1000-2 composite demonstrated significantly enhanced DPPH radical scavenging activity and stronger antibacterial effects against
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.